Qlt Inc (QLTI) 1.49 $QLTI
QLT Inc. reports 1Q loss
Automated Insights - Thu May 05, 6:27AM CDT
VANCOUVER, British Columbia (AP) _ QLT Inc. (QLTI) on Thursday reported a loss of $21.9 million in its first quarter.
QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02)
QLT Announces First Quarter 2016 Results
GlobeNewswire - Thu May 05, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
reported financial results today for the first quarter ended March 31, 2016. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.
QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02)
QLT Terminates $20 Million Private Placement
GlobeNewswire - Mon May 02, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced that it has terminated the previously announced US$20 million private placement in QLT. The Company's Board of Directors (the "Board" has determined that it would not be in the best interests of QLT to dilute its existing shareholders.
QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02)
QLT Inc. Completes Enrollment in its Natural History Study
GlobeNewswire - Fri Apr 22, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI); (TSX:QLT) ("QLT" or the "Company" announced today completion of enrollment in its retrospective, uncontrolled, multicenter Natural History Study in subjects with Inherited Retinal Disease (IRD) phenotypically diagnosed with Retinitis Pigmentosa (RP) or Leber Congenital Amaurosis (LCA) due to underlying Retinal Pigment Epithelial 65 protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) gene mutations. The objective of the retrospective, open label study is to gather data on the natural progression of the disease in subjects over time, including from childhood through to adulthood. The study included both subjects who had previously received treatment in QLT-sponsored clinical trials with QLT's synthetic oral retinoid product, QLT091001, as well as subjects who had not received any prior therapeutic treatment. For subjects who had received prior treatment with QLT091001, the study included a retrospective review of subjects' medical records prior to and after treatment with QLT091001.
QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02)
The Zacks Analyst Blog Highlights: QLT, Twitter, Aegerion Pharmaceuticals, Linn and Lenovo Group
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: QLT, Twitter, Aegerion Pharmaceuticals, Linn and Lenovo Group
QLTI: 1.49 (-0.05), LNCO: 0.12 (unch), AEGR: 1.41 (-0.09), TWTR: 14.11 (-0.49)
5 Stocks Near 52-Week Lows But Still Worth Buying
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:31AM CDT
These stocks are priced close to their 52-week low at the moment and offer an excellent bargain to investors.
QLTI: 1.49 (-0.05), LNCO: 0.12 (unch), GOOGL: 734.81 (-7.71), AEGR: 1.41 (-0.09), TWTR: 14.11 (-0.49)
QLT Announces Date of Special Distribution to Shareholders
GlobeNewswire - Mon Apr 04, 7:37AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" is pleased to announce that its previously announced special distribution (the "Special Distribution" of common shares (the "Aralez Shares" of Aralez Pharmaceuticals Inc., or cash in lieu thereof, to QLT shareholders will complete on April 5, 2016 (the "Distribution Date" .
QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02), ARLZ: 3.58 (-0.13)
Should QLT Inc. (QLTI) Be On Your Radar Now?
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:47AM CDT
QLT Inc. has actually seen rising estimates over the past one month and looks well positioned for a solid gain, but has been overlooked by investors
QLTI: 1.49 (-0.05)
QLT Provides Update on Special Distribution to Shareholders
GlobeNewswire - Mon Mar 21, 4:42PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" is providing an update on its previously announced special distribution (the "Special Distribution" of common shares (the "Aralez Shares" of Aralez Pharmaceuticals Inc. ("Aralez" , or cash in lieu thereof, to QLT shareholders.
QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02), ARLZ: 3.58 (-0.13)
Age Related Macular Degeneration Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xs8ntz/age_related) has announced the addition of the "Age Related Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degenerationand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Age Related Macular DegenerationOverview - Therapeutics Development - Pipeline Products for Age Related Macular Degeneration- Overview - Pipeline Products for Age Related Macular Degeneration- Comparative Analysis - Age Related Macular Degeneration- Therapeutics under Development by Companies - Age Related Macular Degeneration- Therapeutics under Investigation by Universities/Institutes - Age Related Macular Degeneration- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Age Related Macular Degeneration- Products under Development by Companies - Age Related Macular Degeneration- Products under Investigation by Universities/Institutes - Age Related Macular Degeneration- Companies Involved in Therapeutics Development Sample List of Companies - AC Immune SA - Allinky Biopharma - Amakem NV - Amarna Therapeutics B.V. - Amyndas Pharmaceuticals LLC - AngioGenex, Inc. - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporation - Avalanche Biotechnologies, Inc. - Clearside BioMedical, Inc. - Colby Pharmaceutical Company - Digna Biotech, S.L. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Lead Discovery Center GmbH - LeadArtis S.L. - Mabion SA - MacuCLEAR, Inc. - Merz Pharma GmbH & Co. KgaA - Mitotech S.A. - Promedior, Inc. - Protelica Incorporated - pSivida Corp. - QLT Inc. - Quark Pharmaceuticals, Inc. - Ra Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RestorGenex Corporation - Ribomic Inc. - RXi Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/xs...ge_related
CLSD: 6.87 (-0.09), QLTI: 1.49 (-0.05), FOMX: 6.74 (-0.16), AAVL: 4.14 (-0.18), REGN: 371.94 (-9.14)
QLT Announces Closing of Acquisition of Shares of Aralez Pharmaceuticals Inc. and Special Distribution to Shareholders
GlobeNewswire - Fri Feb 05, 12:30PM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" today announces that it has acquired 7,200,000 common shares (the "Aralez Shares" of Aralez Pharmaceuticals Inc. ("Aralez" for a per share price of US$6.25 and an aggregate purchase price of US$45 million. Aralez is a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc. which completed today. Commencing on or about February 8, 2016, the common shares of Aralez will trade on NASDAQ under the ticker symbol "ARLZ", and on or about February 10, 2016, will trade on the Toronto Stock Exchange under the ticker symbol "ARZ". In connection with QLT's acquisition of the Aralez Shares, Jason Aryeh, the Chairman of QLT's board of directors, has been appointed to the board of directors of Aralez.
QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02), ARLZ: 3.58 (-0.13), POZN: 5.94 (-0.43)
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.49 (-0.05), ISIS: 57.56 (-0.28), ONCE: 53.59 (+0.04), SHPG: 176.56 (-7.39), SCMP: 11.90 (-0.07), GNST: (), CLBS: 0.56 (+0.03)
QLT Announces Results of Annual Meeting of Shareholders
GlobeNewswire - Tue Jan 12, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" is pleased to announce that, on a vote by ballot, the six incumbent directors of the Company were re-elected at the Company's annual general meeting held on January 8, 2016 (the "Meeting" .
QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02)
World Leber Congenital Amaurosis (LCA) Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 06, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/n7h2f2/leber_congenital) has announced the addition of the "Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber Congenital Amaurosis (LCA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Leber Congenital Amaurosis (LCA) Overview - Therapeutics Development - Pipeline Products for Leber Congenital Amaurosis (LCA) - Overview - Pipeline Products for Leber Congenital Amaurosis (LCA) - Comparative Analysis - Leber Congenital Amaurosis (LCA) - Therapeutics under Development by Companies - Leber Congenital Amaurosis (LCA) - Therapeutics under Investigation by Universities/Institutes - Leber Congenital Amaurosis (LCA) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Leber Congenital Amaurosis (LCA) - Products under Development by Companies - Leber Congenital Amaurosis (LCA) - Products under Investigation by Universities/Institutes - Leber Congenital Amaurosis (LCA) - Companies Involved in Therapeutics Development - AmpliPhi Biosciences Corporation - ProQR Therapeutics N.V. - QLT Inc. - Spark Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/n7...congenital
QLTI: 1.49 (-0.05), ONCE: 53.59 (+0.04), APHB: 1.69 (-0.06)
QLT Calls Special Meeting of Its Shareholders in Connection With Aralez Pharmaceuticals Transaction
GlobeNewswire - Mon Dec 28, 6:00AM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" today announced that it has called a special meeting of its shareholders (the "Special Meeting" to approve a reorganization of its share capital pursuant to a statutory plan of arrangement (the "Share Reorganization" . As discussed below, if approved, the Share Reorganization is expected to permit QLT to distribute common shares of Aralez Pharmaceuticals Inc. ("Aralez" to QLT shareholders in a tax efficient manner. It is anticipated that the Special Meeting will be held on February 11, 2016, in Vancouver, Canada.
QLTI: 1.49 (-0.05), TRX.VN: 1.250 (-0.070), QLT.TO: 1.92 (-0.02), ARLZ: 3.58 (-0.13), POZN: 5.94 (-0.43)
The Road Ahead - Complementary Research on ReachLocal, ReneSola, Sky-mobi and QLT
ACCESSWIRE - Tue Dec 22, 6:55AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: ReachLocal Inc. (NASDAQ: RLOC), ReneSola Ltd. (NYSE: SOL), Sky-mobi Ltd. (NASDAQ: MOBI) and QLT Inc. (NASDAQ: QLTI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SOL: 1.31 (-0.04), QLTI: 1.49 (-0.05), RLOC: 1.69 (-0.06), MOBI: 1.82 (-0.02)
QLT Commences Breach of Contract Action Against Valeant Pharmaceuticals
GlobeNewswire - Wed Dec 16, 6:00AM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced that it has filed a breach of contract lawsuit against Valeant Pharmaceuticals International, Inc. ("Valeant" in the Supreme Court of British Columbia. QLT alleges that Valeant has failed to pay the $5 Million laser earn-out milestone required under the terms of its 2012 Asset Purchase Agreement with Valeant.
QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02), VRX.TO: 31.60 (-0.59)
QLT, Deerfield and Other Leading Healthcare Investors Confirm Their Planned Investment in Aralez Pharmaceuticals, a Canadian Domiciled Entity
GlobeNewswire - Mon Dec 07, 3:54PM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announced today that it has agreed to revised terms regarding its previously announced agreement to provide equity financing in the amount of US$45 million in connection with the pending merger transaction between POZEN Inc. (Nasdaq
OZN) ("POZEN" and Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute" . The revised terms were agreed to in connection with changes to the merger transaction announced earlier today by POZEN and Tribute.
QLTI: 1.49 (-0.05), TRX.VN: 1.250 (-0.070), QLT.TO: 1.92 (-0.02), ARLZ: 3.58 (-0.13), POZN: 5.94 (-0.43)
QLT (QLTI) Reports Narrower-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 11:15AM CDT
QLT Inc. (QLTI) reported a third-quarter 2015 loss of 5 cents per share.
QLTI: 1.49 (-0.05), AMAG: 21.39 (-0.47), ANIK: 49.23 (+0.31)
QLT Inc. reports 1Q loss
Automated Insights - Thu May 05, 6:27AM CDT
VANCOUVER, British Columbia (AP) _ QLT Inc. (QLTI) on Thursday reported a loss of $21.9 million in its first quarter.
QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02)
QLT Announces First Quarter 2016 Results
GlobeNewswire - Thu May 05, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
reported financial results today for the first quarter ended March 31, 2016. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP. QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02)
QLT Terminates $20 Million Private Placement
GlobeNewswire - Mon May 02, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced that it has terminated the previously announced US$20 million private placement in QLT. The Company's Board of Directors (the "Board" has determined that it would not be in the best interests of QLT to dilute its existing shareholders. QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02)
QLT Inc. Completes Enrollment in its Natural History Study
GlobeNewswire - Fri Apr 22, 6:00AM CDT
QLT Inc. (NASDAQ:QLTI); (TSX:QLT) ("QLT" or the "Company"
announced today completion of enrollment in its retrospective, uncontrolled, multicenter Natural History Study in subjects with Inherited Retinal Disease (IRD) phenotypically diagnosed with Retinitis Pigmentosa (RP) or Leber Congenital Amaurosis (LCA) due to underlying Retinal Pigment Epithelial 65 protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) gene mutations. The objective of the retrospective, open label study is to gather data on the natural progression of the disease in subjects over time, including from childhood through to adulthood. The study included both subjects who had previously received treatment in QLT-sponsored clinical trials with QLT's synthetic oral retinoid product, QLT091001, as well as subjects who had not received any prior therapeutic treatment. For subjects who had received prior treatment with QLT091001, the study included a retrospective review of subjects' medical records prior to and after treatment with QLT091001. QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02)
The Zacks Analyst Blog Highlights: QLT, Twitter, Aegerion Pharmaceuticals, Linn and Lenovo Group
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: QLT, Twitter, Aegerion Pharmaceuticals, Linn and Lenovo Group
QLTI: 1.49 (-0.05), LNCO: 0.12 (unch), AEGR: 1.41 (-0.09), TWTR: 14.11 (-0.49)
5 Stocks Near 52-Week Lows But Still Worth Buying
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:31AM CDT
These stocks are priced close to their 52-week low at the moment and offer an excellent bargain to investors.
QLTI: 1.49 (-0.05), LNCO: 0.12 (unch), GOOGL: 734.81 (-7.71), AEGR: 1.41 (-0.09), TWTR: 14.11 (-0.49)
QLT Announces Date of Special Distribution to Shareholders
GlobeNewswire - Mon Apr 04, 7:37AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT"
is pleased to announce that its previously announced special distribution (the "Special Distribution" of common shares (the "Aralez Shares" of Aralez Pharmaceuticals Inc., or cash in lieu thereof, to QLT shareholders will complete on April 5, 2016 (the "Distribution Date" . QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02), ARLZ: 3.58 (-0.13)
Should QLT Inc. (QLTI) Be On Your Radar Now?
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 7:47AM CDT
QLT Inc. has actually seen rising estimates over the past one month and looks well positioned for a solid gain, but has been overlooked by investors
QLTI: 1.49 (-0.05)
QLT Provides Update on Special Distribution to Shareholders
GlobeNewswire - Mon Mar 21, 4:42PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT"
is providing an update on its previously announced special distribution (the "Special Distribution" of common shares (the "Aralez Shares" of Aralez Pharmaceuticals Inc. ("Aralez" , or cash in lieu thereof, to QLT shareholders. QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02), ARLZ: 3.58 (-0.13)
Age Related Macular Degeneration Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xs8ntz/age_related) has announced the addition of the "Age Related Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degenerationand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Age Related Macular DegenerationOverview - Therapeutics Development - Pipeline Products for Age Related Macular Degeneration- Overview - Pipeline Products for Age Related Macular Degeneration- Comparative Analysis - Age Related Macular Degeneration- Therapeutics under Development by Companies - Age Related Macular Degeneration- Therapeutics under Investigation by Universities/Institutes - Age Related Macular Degeneration- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Age Related Macular Degeneration- Products under Development by Companies - Age Related Macular Degeneration- Products under Investigation by Universities/Institutes - Age Related Macular Degeneration- Companies Involved in Therapeutics Development Sample List of Companies - AC Immune SA - Allinky Biopharma - Amakem NV - Amarna Therapeutics B.V. - Amyndas Pharmaceuticals LLC - AngioGenex, Inc. - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporation - Avalanche Biotechnologies, Inc. - Clearside BioMedical, Inc. - Colby Pharmaceutical Company - Digna Biotech, S.L. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Lead Discovery Center GmbH - LeadArtis S.L. - Mabion SA - MacuCLEAR, Inc. - Merz Pharma GmbH & Co. KgaA - Mitotech S.A. - Promedior, Inc. - Protelica Incorporated - pSivida Corp. - QLT Inc. - Quark Pharmaceuticals, Inc. - Ra Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RestorGenex Corporation - Ribomic Inc. - RXi Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/xs...ge_related
CLSD: 6.87 (-0.09), QLTI: 1.49 (-0.05), FOMX: 6.74 (-0.16), AAVL: 4.14 (-0.18), REGN: 371.94 (-9.14)
QLT Announces Closing of Acquisition of Shares of Aralez Pharmaceuticals Inc. and Special Distribution to Shareholders
GlobeNewswire - Fri Feb 05, 12:30PM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT"
today announces that it has acquired 7,200,000 common shares (the "Aralez Shares" of Aralez Pharmaceuticals Inc. ("Aralez" for a per share price of US$6.25 and an aggregate purchase price of US$45 million. Aralez is a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc. which completed today. Commencing on or about February 8, 2016, the common shares of Aralez will trade on NASDAQ under the ticker symbol "ARLZ", and on or about February 10, 2016, will trade on the Toronto Stock Exchange under the ticker symbol "ARZ". In connection with QLT's acquisition of the Aralez Shares, Jason Aryeh, the Chairman of QLT's board of directors, has been appointed to the board of directors of Aralez. QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02), ARLZ: 3.58 (-0.13), POZN: 5.94 (-0.43)
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.49 (-0.05), ISIS: 57.56 (-0.28), ONCE: 53.59 (+0.04), SHPG: 176.56 (-7.39), SCMP: 11.90 (-0.07), GNST: (), CLBS: 0.56 (+0.03)
QLT Announces Results of Annual Meeting of Shareholders
GlobeNewswire - Tue Jan 12, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
is pleased to announce that, on a vote by ballot, the six incumbent directors of the Company were re-elected at the Company's annual general meeting held on January 8, 2016 (the "Meeting" . QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02)
World Leber Congenital Amaurosis (LCA) Therapeutics Pipeline Review, H2 2015
M2 - Wed Jan 06, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/n7h2f2/leber_congenital) has announced the addition of the "Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber Congenital Amaurosis (LCA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Leber Congenital Amaurosis (LCA) Overview - Therapeutics Development - Pipeline Products for Leber Congenital Amaurosis (LCA) - Overview - Pipeline Products for Leber Congenital Amaurosis (LCA) - Comparative Analysis - Leber Congenital Amaurosis (LCA) - Therapeutics under Development by Companies - Leber Congenital Amaurosis (LCA) - Therapeutics under Investigation by Universities/Institutes - Leber Congenital Amaurosis (LCA) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Leber Congenital Amaurosis (LCA) - Products under Development by Companies - Leber Congenital Amaurosis (LCA) - Products under Investigation by Universities/Institutes - Leber Congenital Amaurosis (LCA) - Companies Involved in Therapeutics Development - AmpliPhi Biosciences Corporation - ProQR Therapeutics N.V. - QLT Inc. - Spark Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/n7...congenital
QLTI: 1.49 (-0.05), ONCE: 53.59 (+0.04), APHB: 1.69 (-0.06)
QLT Calls Special Meeting of Its Shareholders in Connection With Aralez Pharmaceuticals Transaction
GlobeNewswire - Mon Dec 28, 6:00AM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT"
today announced that it has called a special meeting of its shareholders (the "Special Meeting" to approve a reorganization of its share capital pursuant to a statutory plan of arrangement (the "Share Reorganization" . As discussed below, if approved, the Share Reorganization is expected to permit QLT to distribute common shares of Aralez Pharmaceuticals Inc. ("Aralez" to QLT shareholders in a tax efficient manner. It is anticipated that the Special Meeting will be held on February 11, 2016, in Vancouver, Canada. QLTI: 1.49 (-0.05), TRX.VN: 1.250 (-0.070), QLT.TO: 1.92 (-0.02), ARLZ: 3.58 (-0.13), POZN: 5.94 (-0.43)
The Road Ahead - Complementary Research on ReachLocal, ReneSola, Sky-mobi and QLT
ACCESSWIRE - Tue Dec 22, 6:55AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: ReachLocal Inc. (NASDAQ: RLOC), ReneSola Ltd. (NYSE: SOL), Sky-mobi Ltd. (NASDAQ: MOBI) and QLT Inc. (NASDAQ: QLTI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SOL: 1.31 (-0.04), QLTI: 1.49 (-0.05), RLOC: 1.69 (-0.06), MOBI: 1.82 (-0.02)
QLT Commences Breach of Contract Action Against Valeant Pharmaceuticals
GlobeNewswire - Wed Dec 16, 6:00AM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced that it has filed a breach of contract lawsuit against Valeant Pharmaceuticals International, Inc. ("Valeant" in the Supreme Court of British Columbia. QLT alleges that Valeant has failed to pay the $5 Million laser earn-out milestone required under the terms of its 2012 Asset Purchase Agreement with Valeant. QLTI: 1.49 (-0.05), QLT.TO: 1.92 (-0.02), VRX.TO: 31.60 (-0.59)
QLT, Deerfield and Other Leading Healthcare Investors Confirm Their Planned Investment in Aralez Pharmaceuticals, a Canadian Domiciled Entity
GlobeNewswire - Mon Dec 07, 3:54PM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company"
announced today that it has agreed to revised terms regarding its previously announced agreement to provide equity financing in the amount of US$45 million in connection with the pending merger transaction between POZEN Inc. (Nasdaq OZN) ("POZEN" and Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute" . The revised terms were agreed to in connection with changes to the merger transaction announced earlier today by POZEN and Tribute. QLTI: 1.49 (-0.05), TRX.VN: 1.250 (-0.070), QLT.TO: 1.92 (-0.02), ARLZ: 3.58 (-0.13), POZN: 5.94 (-0.43)
QLT (QLTI) Reports Narrower-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 11:15AM CDT
QLT Inc. (QLTI) reported a third-quarter 2015 loss of 5 cents per share.
QLTI: 1.49 (-0.05), AMAG: 21.39 (-0.47), ANIK: 49.23 (+0.31)
